4.6 Article

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial

Journal

BMJ OPEN
Volume 12, Issue 8, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-051594

Keywords

chemotherapy; radiotherapy; head & neck tumours

Funding

  1. Applied Research Cultivation Programme of Jiangxi Province [20212BAG70047]
  2. Beijing Xisike Clinical Oncology Research Foundation [Y--XD202001/zb-0002]
  3. Jiangxi Provincial Natural Science Foundation of China [20202BAB206057]
  4. Natural Science Foundation of China [81960544, 81660452]
  5. Project of health commission of Jiangxi province [20191093]

Ask authors/readers for more resources

This study aims to explore individualized treatment strategies for patients with different ICT efficacy, in order to increase treatment intensity for patients with poor efficacy and reduce treatment toxicity for patients with favorable efficacy.
Epidermal growth factor receptor (EGFR) is a therapeutic target in nasopharyngeal carcinoma (NPC). The optimal combined modality of optimal combined modality of anti--EGFR monoclonal antibodies, induction chemotherapy (ICT), concurrent chemotherapy and radiotherapy for NPC remains poorly defined. None of previous studies have developed subsequent treatment strategies on the basis of stratification according to the efficacy following ICT plus anti-EGFR mAbs. This study aims to increase treatment intensity for patients with poor efficacy of ICT and reduce treatment toxicity for patients with favourable efficacy of ICT by assessing whether the efficacy of this treatment regimen is non-inferior to ICT plus concurrent chemoradiotherapy (historic controls). IntroductionMethods and analysis Pathology-confirmed WHO type II/III NPC patients at clinical stage III-IVA (eighth American Joint Committee on Cancer/Union for International Cancer Control staging system) will be included in the study. They will receive ICT plus nimotuzumab (NTZ), followed by radiotherapy plus NTZ or concurrent chemoradiotherapy plus NTZ (stratified based on the efficacy of ICT plus NTZ). The primary endpoint is 3-year failure-free survival rate; while the secondary endpoints are 3-year overall survival rate, distant metastasis-free survival rate and locoregional recurrence-free survival rate, and short-term remission rate of tumour and treatment toxicity. Ethics and dissemination The study protocol has been approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Our findings will be disseminated in a peer-reviewed journal. Implementation strategies are in place to ensure privacy and confidentiality of participants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available